Please provide your email address to receive an email when new articles are posted on . Subcutaneous tocilizumab provides similar exposure and risk-benefit profiles as intravenous tocilizumab in ...
INCHEON, South Korea, Oct. 2, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that AVTOZMA ® (tocilizumab-anoh) intravenous (IV) formulation is now available to patients in the United States.
INCHEON, South Korea, Aug. 6, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Although investigators of a recently ...
The approval of the SC formulation for this patient population was based on data from the JIGSAW-118 study, a 52-week, open-label, multicenter, pharmacokinetic (PK)/pharmacodynamic (PD) study. The ...
Actemra, a humanized interleukin-6 (IL-6) receptor antagonist, is already indicated to treat rheumatoid arthritis, active systemic juvenile idiopathic arthritis, giant cell arteritis, and chimeric ...
Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment “Biosimilars continue to be a key growth driver for Organon, and this acquisition complements ...
AVTOZMA IV is approved for all same indications as the reference product Actemra ® (tocilizumab), including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback